Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Smallpox is an infectious disease that has threatened the survival of human beings, and vaccination against it was proven to be extremely effective. The effects of vaccination have long been noted; literature of ancient People’s Republic of China and India both report a preventive measure involving the use of scabs from patients with smallpox.1,2 Nevertheless, it was not until the modern approach to vaccination was developed by Dr. Jenner that the side effects of vaccines reached acceptable levels. Vaccination has since become a powerful countermeasure against smallpox and has been continuously improved on, becoming widespread throughout the world.2,3 In the 1970s, however, just before the WHO declared the eradication of smallpox, axillary lymphadenopathy was detected as a side effect of the vaccine in approximately 50% of the vaccinated population.4

The coronavirus disease 2019 (COVID-19) pandemic, which started at the end of 2019 and continues to plague the population, is the most serious public health issue in the world now, and the acquisition of immunity through a vaccine is regarded as one of the best countermeasures against this infectious disease. Serious adverse events after COVID-19 vaccination are considered rare; ChAdOx1 nCoV-19/AZD1222 and Ad26.COV2.S have been associated with thrombosis with thrombocytopenia, and the mRNA vaccines have been associated with myocarditis/pericarditis.5–7 In the phase 3 trial leading to emergency use authorization for the Moderna vaccine, adenopathy was reported as an unsolicited event in 1.1% of patients.8 In the clinical trial leading to emergency use authorization for the Pfizer-BioNTech vaccine, the self-reported rate of adenopathy in patients was 0.3%.9

Nishino et al.10 used prevaccine and postvaccine chest computed tomography data of patients with thoracic malignancies who received two doses of mRNA-based COVID-19 vaccinations. The incidence rate was 9%, with a median time of 1.7 weeks after the second booster shot, and female sex and vaccine type (mRNA-1273 vaccine) were revealed to be predisposing factors. The median short-axis diameter of the largest node was 7 mm, and the median number of swollen nodes was four. Nevertheless, the study protocol did not clearly specify the timing of the imaging study, so whether or not the maximum diameter of a swollen lymph node (LN) was accurately captured and how long the swelling continued was unclear. This makes it difficult to focus on how to use the findings obtained clinically.

Vaccine-related lymphadenopathy in patients with lung cancer can lead to conflicting situations owing to disease burden. First, in the early stage, axillary lymphadenopathy can confuse staging, resulting in unnecessarily invasive procedures. Second, in the evaluation of neoadjuvant therapy with a marginally substantial disease stage, it becomes difficult to make treatment decisions. Third, in cases of advanced diseases, it can affect the determination of the treatment effect. Finally, new LNs in completely resected patients make it difficult to distinguish the presence of recurrence.

Vaccine-related lymphadenopathy has been evaluated in a variety of modalities. For example, prevalent ultrasound features include oval form, asymmetric cortex with hilum evidence, and central and peripheral vascular signals at superb microvascular imaging, along with elastosonography patterns resembling the surrounding tissue.11 Positron emission tomography (PET)-computed tomography results of 274 vaccinated cases revealed...
66% positivity and used the maximum standardized uptake value of LN with or without the ipsilateral arm uptake with 55.4% of sensitivity and 83.6% of specificity for the differential diagnosis. Nevertheless, making a differential diagnosis using only diagnostic imaging has limited utility. A similar problem is found in “nodal immune flare” in neoadjuvant immune checkpoint inhibitors.

Vaccine-related lymphadenopathy is also a long-standing problem. Histologic evaluations are essential for a definitive diagnosis, and the histologic features described in some reports have included an increased number of reticular lymphoblasts imparting a mottled appearance to the lymphoid tissue; diffuse, follicular, or combined diffuse and follicular hyperplasia; vascular and sinusoidal changes; and a mixed cellular response. Regarding the COVID-19 vaccine specifically, reported features include a florid, reactive lymphadenopathy pattern characterized by a mixed lymphoid population with lymphocytes at different stages of maturation, including many centroblasts admixed with numerous tingible body macrophages and enlarged germinal center with interfollicular expansion by small lymphocytes, prominent germinal center with tingible body macrophages, and reactive germinal center with expansion of interfollicular regions by small lymphocytes and focally prominent endothelial cells. These changes may reflect the immune response to mRNA vaccination. In brief, the presence of tangible macrophages suggests that cells that have taken up the mRNA may have been processed by phagocytic cells, and the proliferation of follicles and lymphocytes at different stages suggests that memory B cells may have been created. In other words, vaccine-related lymphadenopathy may be a surrogate marker of the effective uptake of the vaccine component.

Accurate noninvasive identification of vaccine-related lymphadenopathy and metastatic LN swelling is challenging, even with modern technologies. The current management strategy is guided by clinical context; accurate records of vaccination information, including dates administered, injection sites, and type of vaccine, and imaging findings within 5 days after vaccination and 6 weeks or more after vaccination and vaccine administration on the contralateral side to the cancer. Because metabolic activity is often observed on 18F-fluorodeoxyglucose (FDG)-PET in a considerable number of cases of vaccine adenopathy, a correct diagnosis can be obtained only by follow-up imaging to ensure shrinkage or by a histopathologic evaluation.

Emerging technologies may help manage this situation. FDG, which captures metabolic activity, has excellent sensitivity for identifying lesions but is not useful for differentiating malignant from benign lesions. Radiolabeled amino acids are well-established agents for PET-based tumor imaging because of their correlation with cellular proliferation with high sensitivity and specificity. Carbon-11(11C)-methionine (MET) has been extensively investigated and may reduce the number of false-positive findings in inflammatory lung disorders. Kubota et al. and Hsieh et al. reported that MET is more specific and sensitive than FDG. A major disadvantage, however, is the need for on-site cyclotron, as 11C is a short half-life isotope (20 min). Besides 11C-MET, the efficacy of new PET tracers is being investigated as a diagnostic tool for distinguishing between malignancies and inflammatory diseases. On the vaccination side, alternate administration methods from the intramuscular approach are also being developed. Compared with intramuscular injection, mucosal administration is less likely to cause adverse reactions because it is not directly administered into the blood. ChAdOx1 nCoV-19 (AZD1222) is an approved adenovirus-based vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and van Doremalen et al. reported that intranasal vaccination with ChAdOx1 nCoV-19 (AZD1222) reduced virus concentrations in nasal swabs in two different SARS-CoV-2 animal models and reduced viral loads in bronchoalveolar lavage and lower respiratory tract tissue. Other oral or intranasal vaccines are currently under development and may contribute to satisfying the clinical need for SARS-CoV-2 vaccines.

Regarding the estimation of the tumor volume, circulating tumor DNA (ctDNA) or circulating tumor cells may be useful molecular markers. Among the various liquid biopsy methods, plasma ctDNA is the most extensively studied and is widely used in clinical practice. In early stage NSCLC, ctDNA detected after curative surgical resection may be informative in identifying patients at a high risk for recurrence. In advanced-stage NSCLC, the quantitation and dynamic change in ctDNA levels after the initiation of treatment helps clinicians predict the efficacy of immune checkpoint blockade therapy before radiographic changes occur.

Considering the timing and duration of lymphadenopathy in daily clinical practice, as revealed in this study, will provide a very useful light for the strategy of the differential diagnosis of COVID-19 mRNA vaccine-related lymphadenopathy, which has been a long-standing problem.

CRediT Authorship Contribution Statement

Katsuhiko Masago, Shiro Fujita: Writing - original draft.

Shiro Fujita: Supervision.

A, Japan Medical Communication/www.japan-mc.co.jp: Writing - review & editing.
References

1. Behbehani AM. The smallpox story: life and death of an old disease. *Microbiol Rev*. 1983;47:455-509.
2. Thèves C, Biagini P, Crubézy E. The rediscovery of smallpox. *Clin Microbiol Infect*. 2014;20:210-218.
3. World Health Organization. Identifying and responding to serious adverse events following immunization: following use of smallpox vaccine during a public health emergency: a guidance document for smallpox vaccine safety surveillance. https://www.who.int/publications/i/item/1066537041. Accessed 2018.
4. Centers for Disease Control and Prevention. Smallpox vaccination and adverse reactions. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5204a1.htm. Accessed 2004.
5. Eichinger S, Warkentin TE, Greinacher A. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *Reply. N Engl J Med*. 2021;385:e11.
6. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384:2092-2101.
7. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70:977-982.
8. Centers for Disease Control and Prevention. The Moderna COVID-19 vaccine’s local reactions, systemic reactions, adverse events, and serious adverse events. https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/safety-surveillance.html. Accessed 2021.
9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *N Engl J Med*. 2020;383:2603-2615.
10. Nishino M, Hatabu H, Ricciuti B, Vaz V, Michael K, Awad MM. Brief report axillary lymphadenopathy after COVID-19 vaccinations in patients with thoracic malignancy: incidence, predisposing factors, and imaging characteristics. *J Thorac Oncol*. 2022;17:154-159.
11. Cocco G, Delli Pizzi A, Fabiani S, et al. Lymphadenopathy after the anti-COVID-19 vaccine: multiparametric ultrasound findings. *Biology (Basel)*. 2021;10:652.
12. Orevi M, Chicheportiche A, Ben-Haim S. Lessons learned from post-COVID-19 vaccination PET/CT studies [e-pub ahead of print]. *J Nucl Med*. https://doi.org/10.2967/jnumed.121.262348, accessed 2021.
13. Cascone T, Weissferdt A, Godoy MCB, et al. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. *Nat Commun*. 2021;12:5045.
14. Hartsough RJ, Bellanti JA. *Postvaccinal lymphadenitis. GP*. 1969;39:99-105.
15. Hagen C, Nowack M, Messerli M, Saro F, Mangold F, Bode PK. Fine needle aspiration in COVID-19 vaccine-associated lymphadenopathy. *Swiss Med Wkly*. 2021;151:w20557.
16. Özyüteniz C, Krystosek LA, Church AL, et al. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncologic patients. *Radiology*. 2021;300:E296-E300.
17. Becker AS, Perez-Johnston R, Chikarmane SA, et al. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel. *Radiology*. 2021;300:E323-E327.
18. Mortazavi S. COVID-19 vaccination-associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women. *AJR Am J Roentgenol*. 2021;217:857-858.
19. Kubota K, Yamada K, Fukuda H, et al. Tumor detection with carbon-11-labelled amino acids. *Eur J Nucl Med*. 1984;9:136-140.
20. Hsieh HJ, Lin SH, Lin KH, Lee CY, Chang CP, Wang SJ. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. *Ann Nucl Med*. 2008;22:533-538.
21. Nishii R, Higashi T, Kagawa S, et al. Diagnostic usefulness of an amino acid tracer, α-[N-methyl-(11C)]-methylaminoisobutyric acid ((11C)-MeAIB), in the PET diagnosis of chest malignancies. *Ann Nucl Med*. 2013;27:808-821.
22. Verhoeven J, Baguet T, Piron S, et al. 2-[18F]FELP, a novel LAT1-specific PET tracer, for the discrimination between glioblastoma, radiation necrosis and inflammation. *Nucl Med Biol*. 2020;82:83-9:16.
23. Watabe T, Ikeda H, Nagamori S, et al. 18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-methionine PET. *Eur J Nucl Med Mol Imaging*. 2017;44:321-331.
24. van Doremalen N, Purushotham JN, Schulz JE, et al. Intranasal ChAdOx1 nCoV-19/ADZ1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. *Sci Transl Med*. 2021;13:eabh0755.
25. Lara-Puente JH, Carreño JM, Sun W, et al. Safety and immunogenicity of a Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX/COVID-12-HEXAPRO (Patria), in pigs [e-pub ahead of print]. *mBio*. https://doi.org/10.1128/mBio.01908-21, accessed 2021.
26. Sam Afkhami MRDA, Zhang A, Stacey HD, et al. Single-dose respiratory mucosal delivery of next-generation viral-vectorized COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. *bioRxiv*. https://www.biorxiv.org/content/10.1101/2021.07.16.452721v1. Accessed 2021.
27. Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for monitoring through liquid biopsies using circulating tumor DNA. *Cancer Discov*. 2017;7:1394-1403.
28. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. *Cancer Discov*. 2017;7:1394-1403.
29. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. *Cancer Discov*. 2020;10:1842-1853.